Emmanuelle Coutanceau joined Novo A/S in September 2015 as Investment Director of Novo Seeds. She led the Series B investments in Corwave, and serves on the Boards of Adenium Biotech, Antag Therapeutics, Avilex Pharma, Corwave, Inthera Bioscience, MinervaX and Pcovery.

Emmanuelle Coutanceau has close to 10 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle Coutanceau was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.

Emmanuelle Coutanceau obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.